Strategies for Continued IRT Success During COVID-19 Date Published: Jun 24, 2020 Article Featured in Journal for Clinical Studies, this article discusses the challenges IRT customers face with the recent COVID-19 pandemic and how to mitigate these potential issues to avoid interrupting ongoing clinical trials. Discover best practices for: Distribution challenges Screening & enrollment challenges A properly configured and adaptive IRT system can enable organizations to remain flexible and agile enough to face any challenge. Signant Health’s team of IRT designers, developers, supply experts, and statisticians are available to consult on challenges and best practices. Download Now Share: LinkedInTweet Recommended Resources Article Conversation with Bill Byrom & Mariana Fontana: Measuring Aspects of Health in Heart Failure Research Dr. Bill Byrom, Principal, eCOA Science at Signant Health, recently had the pleasure of sitting downwith Professor Marianna Fontana, Professor... Download Now Article Conversation with Bill Byrom & Julian Gillmore: Increasing the Usefulness of COAs in Heart Failure Research Dr. Bill Byrom, Principal, eCOA Science at Signant Health, recently had the pleasure of sitting downwith Professor Julian Gillmore, Professor... Download Now Article Optimal COA Measurement Strategy in Modern Oncology Trials The inclusion of patient-reported outcomes (PRO) data in oncology medication labeling in the U.S. has been comparatively limited. Recent FDA... Read Now